409 related articles for article (PubMed ID: 28970836)
21. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
22. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
23. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
[TBL] [Abstract][Full Text] [Related]
24. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
[TBL] [Abstract][Full Text] [Related]
26. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
[TBL] [Abstract][Full Text] [Related]
27. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
28. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
29. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
30. Dietary copper-fructose interactions alter gut microbial activity in male rats.
Song M; Li X; Zhang X; Shi H; Vos MB; Wei X; Wang Y; Gao H; Rouchka EC; Yin X; Zhou Z; Prough RA; Cave MC; McClain CJ
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G119-G130. PubMed ID: 29025734
[TBL] [Abstract][Full Text] [Related]
31. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.
Maestri M; Santopaolo F; Pompili M; Gasbarrini A; Ponziani FR
Front Nutr; 2023; 10():1110536. PubMed ID: 36875849
[TBL] [Abstract][Full Text] [Related]
33. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease, diet and gut microbiota.
Finelli C; Tarantino G
EXCLI J; 2014; 13():461-90. PubMed ID: 26417275
[TBL] [Abstract][Full Text] [Related]
35. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
36. Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis.
Takayama S; Katada K; Takagi T; Iida T; Ueda T; Mizushima K; Higashimura Y; Morita M; Okayama T; Kamada K; Uchiyama K; Handa O; Ishikawa T; Yasukawa Z; Okubo T; Itoh Y; Naito Y
World J Gastroenterol; 2021 May; 27(18):2160-2176. PubMed ID: 34025071
[TBL] [Abstract][Full Text] [Related]
37. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern.
Nier A; Brandt A; Conzelmann IB; Özel Y; Bergheim I
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30235828
[TBL] [Abstract][Full Text] [Related]
38. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
39. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
40. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
